Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.14 | -0.28 | 0.02 | -0.36 |
| FCF Yield | -24.29% | -10.58% | -8.66% | 2.54% |
| EV / EBITDA | -4.22 | -5.33 | -9.71 | 34.41 |
| Quality | ||||
| ROIC | -53.59% | -41.37% | -31.17% | 6.12% |
| Gross Margin | 96.51% | 0.00% | 0.00% | 99.67% |
| Cash Conversion Ratio | 0.86 | 0.77 | 0.90 | 1.17 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | 351.59% |
| Free Cash Flow Growth | -71.17% | -19.94% | -561.69% | 140.70% |
| Safety | ||||
| Net Debt / EBITDA | -0.61 | 1.28 | 0.48 | -7.37 |
| Interest Coverage | -68.91 | -1,105.55 | -48.38 | 13.81 |
| Efficiency | ||||
| Inventory Turnover | 2.26 | 0.00 | -0.11 | 0.06 |
| Cash Conversion Cycle | -4,761.86 | -302,980.42 | -6,914.90 | 1,587.59 |